Dr. Shadi Hamoud | Clinical Trials | Excellence in Research Award
Rambam health care campus | Israel
Dr. Shadi Hamoud is a distinguished physician, clinical researcher, and academic leader whose career spans internal medicine, cardiovascular research, and translational medicine. Earning his medical degree with honors from the Faculty of Medicine at the Hebrew University in Jerusalem, Dr. Hamoud embarked on a professional journey characterized by clinical excellence, research innovation, and a deep commitment to medical education. Over the years, he has combined patient-centered care with groundbreaking research, focusing on lipoprotein oxidation, atherosclerosis, the role of the enzyme heparanase in kidney injury, fatty liver disease, and cardiovascular disorders, as well as pioneering clinical trials for novel oral anticoagulants, lipid-modifying agents, diabetes treatments, and therapies for emerging infectious diseases such as COVID-19.As Deputy Director of the Department of Internal Medicine E at Rambam Medical Center and Director of the Clinical Research Unit, Dr. Hamoud has overseen numerous national and international clinical studies, collaborating with leading pharmaceutical companies, including Bayer, Pfizer, Novartis, Sanofi, and AstraZeneca. His research portfolio reflects expertise in designing and conducting complex multicenter clinical trials addressing some of the most challenging issues in cardiovascular medicine and metabolic diseases. Additionally, his clinical consultancy roles across multiple departments at Rambam Health Care Campus highlight his interdisciplinary approach to medicine, ensuring that research findings translate effectively into improved patient outcomes.An accomplished educator, Dr. Hamoud has dedicated decades to training the next generation of physicians, serving as a clinical lecturer at the Technion-Israel Institute of Technology and mentoring medical students, interns, and graduate researchers. Under his supervision, numerous MD and basic science theses have been completed, exploring critical areas such as oxidative stress, endothelial dysfunction, liver steatosis, and the molecular pathways of atherosclerosis. His leadership as Program Director for the Internal Medicine Preparatory Course for National Licensing Examinations further reflects his commitment to academic excellence and medical training standards.
Profile: Orcid
Featured Publications
Hamoud, S., Hacker, I., Karram, T., Fokra, A., Kabala, A., & Abassi, Z. (2024). Gender-specific renoprotective pathways in αMUPA transgenic mice subjected to acute kidney injury. International Journal of Molecular Sciences.
Cohen-Segev, R., Nativ, O., Kinaneh, S., Aronson, D., Kabala, A., Hamoud, S., Karram, T., & Abassi, Z. (2023). Effects of angiotensin 1-7 and Mas receptor agonist on renal system in a rat model of heart failure. International Journal of Molecular Sciences.
Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R., Zaidani, H., Kabala, A., & Hamoud, S. (2022). Heparanase inhibition prevents liver steatosis in E₀ mice. Journal of Clinical Medicine.
[Author names not fully provided]. (n.d.). Predictors of survival in subjects treated in the “shock room” of the emergency department in a tertiary medical center.